Navigation Links
Driven By Product Innovations, the U.S. Drug Delivery Device Market Will Reach Over $4.5 Billion by 2022
Date:8/6/2014

BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States drug delivery device market will grow at a strong rate to reach a value of over $4.5 billion by 2022 (including device costs only). The future of the drug delivery device market is highly dependent on the pharma industry. Because certain types of drugs are only conducive to specific delivery methods, the kinds of new drugs developed will influence the structure of and innovation in the drug delivery market going forward.

Other key findings from Decision Resources Group's coverage of the U.S. drug delivery device market:

  • Injection devices: Injection devices continue to represent the majority of revenues because diabetic patients largely adopt pen injectors over traditional drug delivery methods, such as insulin pumps or syringes. Leading companies Novo Nordisk, Sanofi and Eli Lilly are also developing new versions or more complex pen injectors, which are expected to launch within the next ten years.
  • AFREZZA inhaler: MannKind recently received approval for the AFREZZA inhaler, which is the first inhaler that can deliver insulin. Because drugs delivered via inhalers are absorbed rapidly by the body, this has the potential to disrupt the traditional insulin delivery device markets. Nonetheless, physicians will need more clinical evidence before the AFREZZA inhaler is widely adopted.
  • Active transdermal patches: Within the transdermal patch market, the development of active patches will enable the treatment of more indications by allowing larger molecules to pass through the skin barrier. The approval of Teva's Zecuity migraine patch in January 2013 represented the first active transdermal patch to become available in the United States.

Comments from Decision Resources Group Senior Analyst Carmen Chan:

  • "A number of new technologies are poised to affect the drug delivery device market in the future. For example, microneedle patches are another type of active patch under development with manufacturers focusing on vaccinations and osteoporosis treatment; both aren't commonly treated with current drug delivery devices."
  • "Subcutaneous implants represent another major product innovation because they eliminate the risk of poor patient compliance, which is currently a significant problem with drug delivery. While current implants serve niche markets, products in development will target widespread conditions like diabetes and hernias."

Additional Resources:

  • Carmen Chan has written a Medtech 360 report on this subject entitled US Markets for Drug Delivery Devices 2014.
  • Decision Resources Group's Pharmacor, which provides a commercial outlook on drugs on the market and in development, can be found here.
  • Decision Resources Group's PatientBase, which determines the total patient and drug-treated populations, can be found here.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

For more information, contact:
Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents
2. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
3. The X-Change Corporation To Announce Corporate Name Change Next Week; New Industry-Driven Branding to Commence For Global Activities, Services, Product Lines, and Website
4. X-Change Corp. Delighted with DOJs Historic Shift Toward Non-Interference Within State Cannabis Regulatory Environments; Sees Green Light for Companys Patient-Driven Medical Cannabis Operations Under State Laws
5. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
6. European Urological Device Market Will Be Driven By Adoption Of New Minimally Invasive Devices
7. W.K. Kellogg Foundation announces Mission Driven Investment in SeeChange Health
8. Food Recalls Driven by Companies Issuing Multiple Recalls in the First Quarter of 2013, According to Latest ExpertRECALL Index
9. The Medical Affairs Function Is a Key Differentiator for Pharma Product Success in Data-Driven Healthcare Market
10. New Telemedicine Market Forecasts Show Software Sales To Reach $2.5 Billion by 2018, Driven by Tablets Like Apples iPad
11. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... -- Perrigo Company plc (NYSE, TASE: PRGO) today announced it has ... for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 ... and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per ... in adults and children 6 years of age and older. ... approximately $16 million.   ...
(Date:2/17/2017)... , Feb 17, 2017 Research and Markets ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:2/17/2017)... partnership with CitiHope , Panexus Haiti ... Jack Brewer Foundation (JBF Worldwide) has sent a ... medicine to Innovating Health International (IHI) in ... to treating chronic diseases and addressing women,s health issues in developing ... and providing these medicines to the organization ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting ... on all facets of clinical trial planning and management. Pharmica discussed the importance ... more. In addition, attendees stopping by Pharmica’s booth were able to demo its ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow ... Tri-Conference February 20 – 22 in San Francisco. As part of the Tri-Conference ... molecular pathology workflow solution, as well as its new precision medicine platform, “Crosswalk ...
(Date:2/17/2017)... ... ... Top neuroendocrine cancer doctors, nurses and specialists from around the world will ... in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive director of ... hosting over 60 faculty members and addressing unmet needs of the NET community. ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... financial planning assistance to families and business owners in the greater Fort Lauderdale ... Families organization. , For more than 30 years, LifeNet 4 Families has ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer survivors, ... final treatments. Physician researchers at The Marcus Institute of Integrative Health at ... efficacy in reducing symptoms of traumatic stress in cancer patients and published ...
Breaking Medicine News(10 mins):